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Abstract
©  2015  Svetlana  F.  Khaiboullina  et  al.  Multiple  sclerosis  (MS)  is  an  autoimmune  and
neurodegenerative disease of unknown etiology. Leukocyte infiltration of brain tissue and the
subsequent inflammation, demyelination, axonal damage, and formation of sclerotic plaques is
a hallmark of MS. Upregulation of proinflammatory cytokines has been suggested to play an
essential  role  in  regulating  lymphocyte  migration  in  MS.  Here  we present  data  on  serum
cytokine expression in MS cases. Increased serum levels of IL-17 and IL-23 were observed,
suggesting activation of the Th17 population of immune effector cells. Additionally, increased
levels of IL-22 were observed in the serum of those with acute phase MS. Unexpectedly, we
observed an upregulation of the serum chemokine CCL27 in newly diagnosed and acute MS
cases. CCL27 is an inflammatory chemokine associated with homing of memory T cells to sites
of inflammation. Therefore, its upregulation in association with MS suggests a potential role in
disease pathogenesis. Our data supports previous reports showing IL-17 and -23 upregulation in
association with MS and potentially identify a previously unknown involvement for CCL27.
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